Company Overview of Kinexum Metabolics, Inc.
Kinexum Metabolics, Inc. operates as a biopharmaceutical company focused on the development of therapies for the treatment of type 1 and type 2 diabetes and other metabolic conditions. It offers INGAP Peptide, an islet neogenesis agent that causes insulin secreting cells to be regenerated from precursor cells. The company was incorporated in 2006 and is based in Edina, Minnesota.
7101 York Avenue South
Edina, MN 55436
Founded in 2006
Key Executives for Kinexum Metabolics, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Kinexum Metabolics, Inc., please visit www.kinexummetabolics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.